ENHANCING THE CIRCULATING HALF LIFE OF ANTIBODY-BASED FUSION PROTEINS
First Claim
1. An antibody-based fusion protein with an enhanced circulating half-life, comprising at least a portion of an immunoglobulin (Ig) heavy chain having substantially reduced binding affinity for an Fc receptor, said portion of heavy chain being linked to a second non-Ig protein, said antibody-based fusion protein having a longer circulating half-life in vivo than an unlinked second non-Ig protein.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
-
Citations
26 Claims
- 1. An antibody-based fusion protein with an enhanced circulating half-life, comprising at least a portion of an immunoglobulin (Ig) heavy chain having substantially reduced binding affinity for an Fc receptor, said portion of heavy chain being linked to a second non-Ig protein, said antibody-based fusion protein having a longer circulating half-life in vivo than an unlinked second non-Ig protein.
-
5. The antibody-based fusion protein of claim , wherein said portion of heavy chain further has binding affinity for an immunoglobulin protection receptor.
- 14. A method of increasing the circulating half-life of an antibody-based fusion protein, comprising the step of linking at least a portion of an Ig heavy chain to a second non-Ig protein, said portion of heavy chain having substantially reduced binding affinity for an Fc receptor, thereby forming an antibody-based fusion protein having a longer circulating half-life in vivo than an unlinked second non-Ig protein.
-
16. A method of increasing the circulating half-life of an antibody-based fusion protein, comprising the steps of:
-
(a) introducing a mutation or a deletion at one or more amino acid of an IgG1 constant region, said amino acid selected from the group consisting of Leu234, Leu235, Gly236, Gly237, Asn297, and Pro331, thereby producing an Ig heavy chain having substantially reduced binding affinity for an Fc receptor; and
(b) linking at least a portion of the heavy chain of step (a) to a second non-Ig protein, thereby forming an antibody-based fusion protein having a longer circulating half-life in vivo than an unlinked second non-Ig protein.
-
-
17. A method of increasing the circulating half-life of an antibody-based fusion protein, comprising the steps of:
-
(a) introducing a mutation or a deletion at one or more amino acid of an IgG3 constant region, said amino acid selected from the group consisting of Leu281, Leu282, Gly283, Gly284, Asn344, and Pro378, thereby producing an Ig heavy chain having substantially reduced binding affinity for an Fc receptor; and
(b) linking at least a portion of the Ig heavy chain of step (a) to a second non-Ig protein, thereby forming an antibody-based fusion protein having a longer circulating half-life in vivo than an unlinked second non-Ig protein.
-
Specification